MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia July 27, 2026 8:00 AM EDT
Company Participants
Christopher Kroeger – Founder, President, CEO & Director
Erin Foff – Chief Medical Officer
Conference Call Participants
Marc Goodman – Leerink Partners LLC, Research Division
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Lin Tsai – Jefferies LLC, Research Division
Michael Riad – Morgan Stanley, Research Division
François Brisebois – LifeSci Capital, LLC, Research Division
Sumant Kulkarni – Canaccord Genuity Corp., Research Division
Joseph Thome – TD Cowen, Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Presentation
Operator
Good day, and welcome to the top line results from the Phase II ZEPHYR study of ML-007C-MA in schizophrenia. [Operator Instructions] As a reminder, this call may be recorded.
I would now like to turn the call over to Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics. Please go ahead.
Christopher Kroeger
Founder, President, CEO & Director
Good morning, everyone, and thank you for joining us. I’m Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight Therapeutics. Today, we’re going to walk through top line data from our Phase II ZEPHYR trial evaluating ML-007C-MA in schizophrenia. I’m joined by our Chief Medical Officer, Dr. Erin Foff, who will take you through the study design and results in detail. Before we get started, I’d like to remind everyone that this presentation contains forward-looking statements that are subject to risks and uncertainties as described in our risk factors in our filings with the SEC.
Let me quickly walk you through today’s agenda. I’ll start with an overview of the ZEPHYR results, followed by a brief outline of the significant remaining unmet need in the treatment of schizophrenia and the ways in which we believe the data from the ZEPHYR study